Innovation and Growth Strategy
Clinical development study teams must content with many challenges and complexities in developing and executing clinical trials. Drug discovery and development is a complex and time-consuming process that faces numerous challenges despite ongoing innovation. These challenges are inherent to the field and can significantly impact the development of new medications.
Despite these challenges, and to support our customers, Q² Solutions continues to innovate through organic internal investments, via strategic partnerships, and by acquisitions. Our growth strategy is a carefully calibrated blend of in-house innovation and strategic acquisitions, aimed at providing our clients with access to the latest scientific capabilities, solutions, and expertise.
Organic Internal Investment
We are continually examining our solutions based on market and client dynamics. This starts by developing a clear and comprehensive strategic plan based on investing in cutting-edge equipment and infrastructure, including upgrading or expanding existing facilities, to meet the demands of our clients. We are also committed to develop our in-house scientific and operational talent by investing in training and development programs. This ensures our staff is skilled and knowledgeable in the latest laboratory techniques and technologies. Q² Solutions allocates resources to research and development with our laboratories encouraging our teams to explore innovative methodologies and stay at the forefront of scientific advancements.
Whether you work with us on a single study or a hundred studies, we want to help you achieve the results you need as fast as you need them now and in the future. The specific elements of our partnership models vary depending on the sponsor’s needs, but hallmarks of our strategic partnerships include a set of operating principles and common language with senior level oversight responsible for account management and service delivery aimed at assuring quality, generating costs savings, improving processes, and enabling innovation.
Creating and executing an effective acquisition strategy involves a systematic approach to identify, evaluate, and integrate potential acquisitions. The right acquisition can bring immediate technology and expertise to client solutions providing access to a more comprehensive suite of diagnostic or research services in one place. In addition, acquired laboratories often come with a team of highly specialized and experienced professionals which clients can leverage for more accurate testing, interpretation, and consultation.
Our innovation strategy is categorized into Science, Digital, and Operational solutions:
- Science Innovation: Scientific innovations are transforming the drug development landscape, making the process more efficient, cost-effective, and precise. At the forefront of genomics, flow cytometry, anatomic pathology, and other laboratory techniques, we’ve been delivering cutting-edge solutions since day one, with a continuous investment in our extensive testing capabilities. Our scientific advisors are at your disposal to consult with on protocol design, assay development, and companion diagnostic development, helping to assure there’s no delay in your decision making.
- Digital Innovation: At Q² Solutions, we have a dedicated Digital Innovation department focused on driving operational improvements and quality of our services. Using the Labmatrix® platform, a BioFortis (a Q² Solutions Company) technology, we’ve helped create agile and impactful solutions across the organization with the underpinnings of traceability, productivity, quality, and efficiency.
- Operational Innovation: In the summer of 2021, Q² Solutions opened a new state of the art, custom designed laboratory space, known as Q² Solutions Innovation Laboratories. Located on the new IQVIA Innovation Park Campus, in the heart of the dynamic Research Triangle Park in central North Carolina, this facility creates an innovative scientific community that includes multiple laboratory disciplines from service lines including Large Molecule Bioanalytical, Vaccines Center of Excellence, Genomics Center of Excellence and Translational Science and Innovation Laboratory (TSAIL).